[Translation] Phase III clinical study of AL8326 tablets in the treatment of patients with small cell lung cancer who have had disease progression or recurrence after at least two lines of treatment
主要目的
评价AL8326片单药治疗二线及以上系统性方案治疗后复发或进展的小细胞肺癌患者的总生存期(OS)疗效。
次要目的
评价AL8326片单药在二线及以上系统性方案治疗后复发或进展的小细胞肺癌患者中的无进展生存期(PFS)和其他有效性指标.
[Translation] Primary objective
To evaluate the overall survival (OS) efficacy of AL8326 tablets as a single agent in patients with small cell lung cancer who have relapsed or progressed after second-line or higher systemic treatment.
Secondary objective
To evaluate the progression-free survival (PFS) and other efficacy indicators of AL8326 tablets as a single agent in patients with small cell lung cancer who have relapsed or progressed after second-line or higher systemic treatment.